The regulation of MDM2 oncogene and its impact on human cancers

被引:132
|
作者
Zhao, Yuhan [1 ]
Yu, Haiyang [1 ]
Hu, Wenwei [1 ,2 ]
机构
[1] Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ 08903 USA
[2] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Pediat, Dept Pharmacol, New Brunswick, NJ 08903 USA
基金
美国国家卫生研究院;
关键词
MDM2; E3 ubiquitin ligase; gene regulation; p53; TUMOR-SUPPRESSOR PATHWAY; P53-MDM2 FEEDBACK LOOP; UBIQUITIN LIGASE ACTIVITY; RIBOSOMAL-PROTEIN L26; LI-FRAUMENI-SYNDROME; DNA-DAMAGE; ACTIVATES P53; MUTANT P53; P53-DEPENDENT MANNER; ONCOPROTEIN MDM2;
D O I
10.1093/abbs/gmt147
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumor suppressor p53 plays a central role in preventing tumor formation. The levels and activity of p53 is under tight regulation to ensure its proper function. Murine double minute 2 (MDM2), a p53 target gene, is an E3 ubiquitin ligase. MDM2 is a key negative regulator of p53 protein, and forms an auto-regulatory feedback loop with p53. MDM2 is an oncogene with both p53-dependent and p53-independent oncogenic activities, and often has increased expression levels in a variety of human cancers. MDM2 is highly regulated; the levels and function of MDM2 are regulated at the transcriptional, translational and post-translational levels. This review provides an overview of the regulation of MDM2. Dysregulation of MDM2 impacts significantly upon the p53 functions, and in turn the tumorigenesis. Considering the key role that MDM2 plays in human cancers, a better understanding of the regulation of MDM2 will help us to develop novel and more effective cancer therapeutic strategies to target MDM2 and activate p53 in cells.
引用
收藏
页码:180 / 189
页数:10
相关论文
共 50 条
  • [1] Regulation of the mdm2 oncogene by thyroid hormone receptor
    Qi, JS
    Yuan, Y
    Desai-Yajnik, V
    Samuels, HH
    MOLECULAR AND CELLULAR BIOLOGY, 1999, 19 (01) : 864 - 872
  • [2] Genomic organisation of the human MDM2 oncogene and relationship to its alternatively spliced mRNAs
    Liang, HL
    Atkins, H
    Abdel-Fattah, R
    Jones, SN
    Lunec, J
    GENE, 2004, 338 (02) : 217 - 223
  • [3] MDM2 regulation of MYC and MYCN in pediatric neural cancers
    Tran, Hung N.
    Qi, Donglai
    Cobrinik, David
    CANCER RESEARCH, 2016, 76
  • [4] MDM2 oncogene as a novel target for human cancer therapy
    Zhang, RW
    Wang, H
    CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (04) : 393 - 416
  • [5] The mdm2 proto-oncogene
    Haines, DS
    LEUKEMIA & LYMPHOMA, 1997, 26 (3-4) : 227 - 238
  • [6] Thrombospondin-1 regulation by MDM2 in aggressive cancers
    Dondapati, Priya
    Maragh, Jason
    Mangrola, Karna
    Alaseem, Ali
    Cheema, Khadija
    Venkatesan, Thiagarajan
    Dhandayuthapani, Sivanesan
    Rathinavelu, Appu
    CANCER RESEARCH, 2017, 77
  • [7] Genomic mapping of the human MDM2 oncogene and the relationship between exon/intron boundaries and variant MDM2 transcripts
    Liang, H
    Atkins, H
    Lunec, J
    BRITISH JOURNAL OF CANCER, 1998, 78 : 64 - 64
  • [8] REGULATION OF MDM2 ONCOGENE BY HELICOBACTER PYLORI LIPOPOLYSACCHARIDE IN GASTRIC EPITHELIAL CELLS
    Pan, X.
    Zhang, G.
    HELICOBACTER, 2011, 16 : 101 - 101
  • [9] Oncogene Mdm2 takes part in hepatocarcinogenesis
    Luo YulinCheng Ruixue Department of PathologyXiangya Medical College Zhongnan UniversityChangsha Huang Guxiang Departement of GeratologyThe Second Xiangya Hospital Xiangya Medical CollegeZhongnan UniversityChangsha
    中国现代医学杂志, 2001, (07) : 1 - 4
  • [10] Overexpression of the MDM2 oncogene in leukemia and lymphoma
    Watanabe, T
    Ichikawa, A
    Saito, H
    Hotta, T
    LEUKEMIA & LYMPHOMA, 1996, 21 (5-6) : 391 - 397